Separately, Jefferies Group initiated coverage on Odonate Therapeutics in a report on Tuesday. They issued a “buy” rating for the company.
Shares of Odonate Therapeutics (NASDAQ ODT) opened at $25.00 on Tuesday. Odonate Therapeutics has a twelve month low of $22.31 and a twelve month high of $25.36.
In related news, Director Boxer Capital, Llc bought 416,666 shares of Odonate Therapeutics stock in a transaction dated Wednesday, December 6th. The stock was acquired at an average cost of $24.00 per share, with a total value of $9,999,984.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin C. Tang bought 1,291,666 shares of Odonate Therapeutics stock in a transaction dated Thursday, December 7th. The shares were bought at an average cost of $24.00 per share, with a total value of $30,999,984.00. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 1,709,332 shares of company stock valued at $41,023,268.
COPYRIGHT VIOLATION WARNING: “Odonate Therapeutics (ODT) Now Covered by Cowen” was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.truebluetribune.com/2018/01/02/odonate-therapeutics-odt-now-covered-by-cowen.html.
About Odonate Therapeutics
Odonate Therapeutics, LLC is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC).
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.